Φαρμακευτικο Μαρκετινγκ: Θεωρια, Πρακτικη, Δεοντολογια

The ultimate guide for Pharma Marketing Champions

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023

Εγκαταλείπεται το Πληροφοριακό Σύστημα Τιμών Φαρμάκων

Την ανάκληση της απόφασης ένταξης του Πληροφοριακού Συστήματος Τιμών Φαρμάκων στο Επιχειρησιακό Πρόγραμμα «Ψηφιακή Σύγκλιση» αποφάσισε το υπουργείο Ανάπτυξης.

Σύμφωνα με τη σχετική απόφαση, ανάκλησης η διαδικασία τροποποίησης της πράξης και οι αλλαγές στο νομοθετικό πλαίσιο δεν επιτρέπουν την εύρυθμη υλοποίηση του Πληροφοριακού Συστήματος Τιμών Φαρμάκων.

Social media changes attitudes to medicines

InPharm | Andrew McConaghie

A third of US social media users say it could change the way they think about their medicines, according to a new poll.

The findings are part of a new survey which confirms the power of social networking to spread information about health, and influence consumers through authoritative sources and through peers and other online influencers.

The survey by consultants PwC’s US-based Health Research Institute (HRI) entitled, “Social media likes healthcare: From marketing to social business” has found that social media is changing how people engage in healthcare decisions, and with healthcare providers.

Pfizer - Amgen dissolving Enbrel partnership

Pfizer  and Amgen  are sorting out responsibilities, and people, over Enbrel, as it unwinds a North American marketing agreement. Amgen is taking on promotion for the blockbuster anti-inflammatory drug.

Starting July 23, Amgen assumes field sales activities in the U.S. and Puerto Rico, but not Canada, the companies told The Wall Street Journal.

Abbott reports strong sales growth in first quarter

The healthcare company's global sales total for the three-month period came to $3.72 billion (2.32 billion pounds), an increase of nearly six percent when excluding the impact of foreign exchange.

During the quarter, Abbott was able to announce a number of new product launches and strategic partnerships to bolster its portfolio, while reporting positive clinical trial data on key therapies such as Humira.

As a result of this performance, the firm has raised its ongoing earnings-per-share outlook for the 2012 full year to between $5.00 and $5.10, up from $4.95 to $5.05.

Boehringer Ingelheim to expand stroke awareness campaign in 2012

Boehringer Ingelheim has announced plans to expand its stroke awareness campaign «1 Million - 1 Mission» with a new phase this year.

The initiative - which is sponsored by Boehringer Ingelheim in collaboration with AntiCoagulation Europe, the Atrial Fibrillation Association, the Stroke Alliance for Europe and the World Heart Federation - is set to enter a new phase that will highlight the link between atrial fibrillation (AF) and stroke.